Karyopharm Therapeutics I... (KPTI)
NASDAQ: KPTI
· Real-Time Price · USD
5.96
1.31 (28.17%)
At close: Aug 15, 2025, 3:59 PM
5.60
-6.01%
After-hours: Aug 15, 2025, 07:58 PM EDT
Karyopharm Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 137.27M | 142.13M | 145.24M | 148.44M | 145.67M | 140.46M | 146.03M | 145.87M | 146M | 148.1M | 157.07M | 249.76M | 251.31M | 234.23M | 209.82M | 118.65M | 102.29M | 113.21M |
Cost of Revenue | 4.98M | 5.49M | 6.18M | 6.42M | 6.03M | 5.66M | 5.02M | 5.32M | 5.39M | 5.14M | 5.21M | 4.09M | 3.7M | 3.9M | 3.4M | 3.71M | 3.56M | 2.82M |
Gross Profit | 132.29M | 136.64M | 139.05M | 142.03M | 139.64M | 134.8M | 141.01M | 140.54M | 140.61M | 142.96M | 151.86M | 245.68M | 247.61M | 230.33M | 206.42M | 114.94M | 98.73M | 110.39M |
Operating Income | -115.21M | -118.94M | -119.44M | -125.97M | -130.95M | -132.4M | -129.54M | -125.6M | -125.18M | -138.51M | -142.2M | -61.37M | -74.34M | -80.48M | -98.27M | -182.3M | -185.6M | -176.87M |
Interest Income | 4.93M | 6.24M | 7.4M | 8.44M | 9.36M | 10.25M | 10.94M | 9.76M | 7.67M | 5.13M | 2.36M | 1.08M | 520K | 392K | 582K | 923K | 1.43M | 2.11M |
Pretax Income | -123.57M | -62.5M | -76.36M | -87.18M | -89.63M | -146M | -142.78M | -139.5M | -141.29M | -157.72M | -164.92M | -87.89M | -103.32M | -107.82M | -123.82M | -205.78M | -207.52M | -200.36M |
Net Income | -123.57M | -62.52M | -76.42M | -87.48M | -89.91M | -146.34M | -143.1M | -139.77M | -141.59M | -158.02M | -165.29M | -88.06M | -103.55M | -108.07M | -124.09M | -206.23M | -207.91M | -200.76M |
Selling & General & Admin | 110.65M | 113.24M | 115.44M | 118.94M | 122.11M | 125.52M | 131.88M | 135.84M | 139.68M | 142.54M | 145.4M | 145.31M | 145.77M | 144.96M | 143.85M | 143.21M | 139.08M | 133.39M |
Research & Development | 136.84M | 142.33M | 143.06M | 149.06M | 148.48M | 141.67M | 138.67M | 130.3M | 126.11M | 138.94M | 148.66M | 161.73M | 176.18M | 165.85M | 160.84M | 154.02M | 145.25M | 153.87M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | 30K | 30K | 17K | 33K | -10K | -83K | -548K | -546K | -97K | -85K | 776K | 617K | 120K |
Operating Expenses | 247.49M | 255.58M | 258.5M | 268M | 270.59M | 267.2M | 270.55M | 266.14M | 265.79M | 281.48M | 294.06M | 307.05M | 321.95M | 310.82M | 304.69M | 297.24M | 284.33M | 287.25M |
Interest Expense | 44.81M | 42.53M | 37.42M | 32.43M | 27.11M | 23.95M | 23.82M | 23.5M | 23.54M | 24.07M | 25M | 27.05M | 28.95M | 27.64M | 26.05M | 25.18M | 23.97M | 25.73M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 3.25M | 3.25M | 3.25M |
Cost & Expenses | 252.48M | 261.07M | 264.68M | 274.41M | 276.62M | 272.86M | 275.57M | 271.47M | 271.18M | 286.62M | 299.28M | 311.13M | 325.65M | 314.71M | 308.09M | 300.95M | 287.89M | 290.07M |
Income Tax Expense | -77K | -50K | 57K | 296K | 280K | 340K | 323K | 266K | 299K | 293K | 369K | 175K | 236K | 249K | 268K | 451K | 389K | 392K |
Shares Outstanding (Basic) | 8.62M | 8.47M | 8.39M | 8.33M | 8.07M | 7.7M | 7.65M | 7.63M | 7.61M | 7.57M | 6M | 5.35M | 5.31M | 5.17M | 5.04M | 5.03M | 5.01M | 4.97M |
Shares Outstanding (Diluted) | 8.62M | 8.47M | 8.39M | 8.33M | 10.29M | 7.7M | 7.65M | 7.63M | 7.61M | 7.57M | 6M | 5.35M | 5.31M | 5.17M | 5.79M | 5.03M | 5.01M | 4.97M |
EPS (Basic) | -14.61 | -8.04 | -10.12 | -11.92 | -12.59 | -19.13 | -18.79 | -19.74 | -22.01 | -26.97 | -30.46 | -16.36 | -19.87 | -21.32 | -24.87 | -41.38 | -42 | -40.82 |
EPS (Diluted) | -14.61 | -13.26 | -15.34 | -17.14 | -17.81 | -19.13 | -18.79 | -19.74 | -22.01 | -26.97 | -30.46 | -17.35 | -20.86 | -22.31 | -25.86 | -41.38 | -42 | -40.82 |
EBITDA | -76.92M | -19.64M | -38.6M | -54.42M | -62.19M | -121.72M | -118.42M | -115.44M | -117.08M | -132.92M | -139.31M | -60.19M | -73.72M | -79.46M | -96.98M | -179.69M | -182.6M | -173.67M |
EBIT | -78.76M | -19.97M | -38.94M | -54.76M | -62.52M | -122.05M | -118.95M | -116M | -117.75M | -133.66M | -139.93M | -60.84M | -74.37M | -80.19M | -97.77M | -180.6M | -183.55M | -174.64M |
Depreciation & Amortization | 320K | 333K | 340K | 336K | 333K | 325K | 530K | 566K | 668K | 734K | 621K | 647K | 651K | 731K | 789K | 907K | 956K | 965K |